Related Experiment Video
Updated: Mar 28, 2026
19:57
An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
19.5K
Virologic Tools for HCV Drug Resistance Testing
Slim Fourati1, Jean-Michel Pawlotsky2
1National Reference Center for Viral Hepatitis B, C, and D; Department of Virology, Hôpital Henri Mondor, Université Paris-Est and INSERM U955, Créteil 94010, France. slim.fourati@aphp.fr.
Viruses
|December 23, 2015
Summary
Direct-acting antivirals (DAAs) offer new Hepatitis C Virus (HCV) treatments. This review details tools for monitoring drug resistance in HCV patients during development and clinical practice.
Area of Science:
- Virology
- Pharmacology
- Molecular Biology
Background:
- Hepatitis C Virus (HCV) treatments have advanced with direct-acting antivirals (DAAs).
- HCV's genetic variability can lead to resistance against DAAs through amino-acid substitutions.
- Monitoring resistance is crucial for effective DAA therapy.
Purpose of the Study:
- To review tools for investigating drug resistance to DAAs.
- To cover resistance monitoring in preclinical studies, clinical trials, and patient care.
Main Methods:
- Literature review of diagnostic and monitoring tools for HCV DAA resistance.
- Analysis of methods used in drug development and clinical settings.
Main Results:
- Various tools exist for detecting and monitoring HCV drug resistance.
- These tools are applicable across different stages, from drug development to clinical practice.
Conclusions:
- Accurate diagnostic tools are essential for managing DAA therapy in Hepatitis C.
- Understanding and monitoring resistance ensures optimal outcomes for patients receiving DAAs.
